Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice?
Archives of Internal MedicinePublished 11 June 2001
Andrew Evans, Lalit Kalra
Citations120
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Patients who undergo anticoagulation for atrial fibrillation in actual clinical practice differ from those in randomized trials, but have similar rates of stroke and major bleeding.
Abstract
Patients who undergo anticoagulation for atrial fibrillation in actual clinical practice differ from those in randomized trials, but have similar rates of stroke and major bleeding. The risk of minor bleeding is higher and may require more intensive monitoring in practice.
Keywords
MedicineEconomics, Econometrics and Finance
The LancetPLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION
1,826 Citations1989Palle Petersen, J Godtfredsen +3 more
The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly.
CirculationStroke Prevention in Atrial Fibrillation Study. Final results.
1,712 Citations1991
Aspirin and warfarin are both effective in reducing ischemic stroke and systemic embolism in patients with atrial fibrillation and patients with nonrheumatic atrialfibrillation who can safely take either aspirin or warfarIn should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
New England Journal of MedicineThe Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
1,535 Citations1990Daniel E. Singer
Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring.
Journal of the American College of CardiologyCanadian atrial fibrillation anticoaguiation (CAFA) study
1,119 Citations1991Stuart J. Connolly, Andreas Laupacis +4 more
The LancetAdjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
1,095 Citations1996
Low-intensity, fixed-dose warfarin plus aspirin in this regimen is insufficient for stroke prevention in patients with non-valvular AF at high-risk for thromboembolism; adjusted-doseWarfarin (target INR 2.0-3.0) importantly reduces stroke for high- risk patients.
BMJPublication bias: evidence of delayed publication in a cohort study of clinical research projects
829 Citations1997Jerome M Stern, R. J. Simes
BMJThe unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials
773 Citations1998Regina Kunz, Andrew D Oxman
On average, failure to use randomisation or adequate concealment of allocation resulted in larger estimates of effect due to a poorer prognosis in non-randomlyselected control groups compared with randomly selected control groups.
Annals of Internal MedicineThe Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
557 Citations1996Stephan D. Fihn, Catherine M. Callahan +4 more
This study analyzed data from six anticoagulation clinics to determine whether elderly patients who were receiving warfarin had a higher incidence of complications than similar younger patients who are also receiving warFarin.
StrokeAcute Stroke With Atrial Fibrillation
521 Citations1996Henrik Jørgensen, Hirofumi Nakayama +3 more
Stroke in patients with AF is generally more severe and outcome markedly poorer than in Patients with sinus rhythm, which accentuates the importance of anticoagulant treatment of individuals with AF.
BMJMethods in health services research: Interpreting the evidence: choosing between randomised and non-randomised studies
397 Citations1999Martin McKee, Annie Britton +4 more
A brief summary of a more detailed review of the impact of potential threats to validity of evaluative research and possible solutions.
The LancetPrevalence of atrial fibrillation and eligibility for anticoagulants in the community
384 Citations1998M. Sudlow, Richard Thomson +3 more
Efforts to promote and support wider and more appropriate use of anticoagulants would seem to be justified, and should decrease the incidence of stroke amongst elderly patients, who may be the most likely to benefit.
JAMAAcetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation
377 Citations1998Elaine M. Hylek
The data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting, and increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulations.
Mayo Clinic ProceedingsBleeding and Thromboembolism During Anticoagulant Therapy:A Population-Based Study in Rochester, Minnesota
276 Citations1995Michael Gitter, Thomas M. Jaeger +3 more
In this population-based study, including a high proportion of elderly patients, malignant disease at initiation of warfarin anticoagulation was significantly associated with both major hemorrhage and any thromboembolism.
Annals of Internal MedicineAtrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention
267 Citations1999Robert G. Hart, Jonathan L. Halperin
Adjusted-dose warfarin has the remarkable potential to reverse almost entirely the increased risk for cardioembolic stroke that accompanies atrial fibrillation and was not substantially offset by major hemorrhage in the randomized trials.
Archives of Internal MedicineAnticoagulation in Atrial Fibrillation
225 Citations1994Lawrence K. Gottlieb
This study illustrates two common problems in attempting to apply the results of randomized clinical trials to routine practice: differences between community patient populations and those on which the conclusions of clinical trials are based, and less successful application of therapeutic interventions in settings other than that of a controlled clinical trial.
StrokeRelationship of cardiac disease to stroke occurrence, recurrence, and mortality.
218 Citations1992Joe Broderick, St. J. Phillips +3 more
Significant independent predictors of death were age, prior myocardial infarction, atrial fibrillation present at onset of stroke, congestive heart failure before the stroke, and an age x congestiveheart failure interaction.
Archives of Internal MedicineNational Patterns of Warfarin Use in Atrial Fibrillation
211 Citations1996Randall S. Stafford
Although it is unrealistic to expect universal warfarin use, the 1992 and 1993 rate of 32% is probably suboptimal given the benefit of anticoagulation in preventing embolic strokes.
The LancetDecision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation
177 Citations2000Richard Thomson, David Parkin +3 more
A Markov decision analysis was done to model decision-making with regard to warfarin treatment in patients with atrial fibrillation, and the model was used to develop evaluative guidelines.
BMJImplementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation
167 Citations1999A J Howitt, David Armstrong
Patients' unwillingness to take warfarin seemed to be a major factor in limiting the number who would eventually take it, and Qualitative data obtained during the interviews suggested that patients' health beliefs were important factors in determining their choice of treatment.
Archives of Internal MedicineStatus of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals
160 Citations1996Gregory W. Albers
About half of the patients with atrial fibrillation admitted to these academic hospitals had clinical risk factors that are associated with increased risk of stroke and no contraindications to anticoagulation, and antithrombotic therapy was underused.
BMJProspective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
151 Citations2000Lalit Kalra
Rates of stroke and major haemorrhage after anticoagulation in clinical practice were comparable to those obtained from pooled data from randomised controlled studies for patients with atrial fibrillation at high risk of stroke.
PubMedComparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic.
80 Citations1993Jill P. Pell, B McIver +3 more
The anticoagulant control achieved in a general practice setting was superior to that in a dedicated hospital outpatient clinic, although control was far from ideal in either setting.
PubMedAnticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
61 Citations1999J. Jaime, K. M. Flegel +4 more
The relative effect of anticoagulant therapy with warfarin in preventing stroke in patients with atrial fibrillation in these practice settings was equivalent to that in the randomized trials, although these patients were older and sicker.
Health Policy and PlanningStroke: the global burden
60 Citations1995Alex Kalache, Isabella Aboderin
This review aims to generate a better understanding of the present and projected future global burden of stroke, with particular emphasis on the non-established market economy countries (NEMEC).
New England Journal of MedicineAiming for Safe Anticoagulation
42 Citations1995Stephan D. Fihn
Since its discovery more than 50 years ago, warfarin has endured as a remarkable drug and is now the 14th-largest-selling medication in the United States.
BMJFortnightly review: Anticoagulation in heart disease
24 Citations1999S Hardman, Martín Cowie
The use of warfarin and heparin in patients with heart disease is discussed and large well conducted double blind randomised trials are chosen when they were the only available evidence.
Clinical Drug InvestigationOutcomes of Long-Term Anticoagulation in Frail Elderly Patients with Atrial Fibrillation
9 Citations1999Gregory Goldenberg, Felix A. Silverstone +2 more
The patients in this study had a rate of bleeds higher than in reported clinical trials, and their older age and greater co-morbidity were the likely causes of this difference.